Trim40 promotes neddylation of IKKγ and is downregulated in gastrointestinal cancers

Carcinogenesis

Volumn 32, Issue 7, 2011, Pages 995-1004

  Noguchi, Keita ^a   Okumura, Fumihiko ^a   Takahashi, Norihiko ^a   Kataoka, Akihiko ^a   Kamiyama, Toshiya ^a   Todo, Satoru ^a   Hatakeyama, Shigetsugu ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B KINASE GAMMA; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NEDD8 PROTEIN; TRIPARTITE MOTIF PROTEIN 40; TRIPARTITE MOTIF PROTEIN 5; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CARCINOGENESIS; DIGESTIVE SYSTEM CANCER; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE EPITHELIUM CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN NEDDYLATION; PROTEIN PROTEIN INTERACTION; RING FINGER MOTIF; SMALL INTESTINE;

EID: 79960063338     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr068     Document Type: Article

References (42)

1. Reymond, A. et al. (2001) The tripartite motif family identifies cell compartments. EMBO J., 20, 2140-2151.
2. Urano, T. et al. (2002) Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature, 417, 871-875.
3. Gack, M.U. et al. (2007) TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature, 446, 916-920.
4. Quaderi, N.A. et al. (1997) Opitz G/BBB syndrome, a defect of midline development, is due to mutations in a new RING finger gene on Xp22. Nat. Genet., 17, 285-291.
5. Avela, K. et al. (2000) Gene encoding a new RING-B-box-Coiled-coil protein is mutated in mulibrey nanism. Nat. Genet., 25, 298-301.
6. Miyajima, N. et al. (2008) TRIM68 regulates ligand-dependent transcription of androgen receptor in prostate cancer cells. Cancer Res., 68, 3486-3494.
7. Kano, S. et al. (2008) Tripartite motif protein 32 facilitates cell growth and migration via degradation of Abl-interactor 2. Cancer Res., 68, 5572-5580.
8. Kikuchi, M. et al. (2009) TRIM24 mediates ligand-dependent activation of androgen receptor and is repressed by a bromodomain-containing protein, BRD7, in prostate cancer cells. Biochim. Biophys. Acta, 1793, 1828-1836.
9. Kamitani, T. et al. (1997) Characterization of NEDD8, a developmentally down-regulated ubiquitin-like protein. J. Biol. Chem., 272, 28557-28562.
10. Lammer, D. et al. (1998) Modification of yeast Cdc53p by the ubiquitinrelated protein rub1p affects function of the SCFCdc4 complex. Genes Dev., 12, 914-926.
11. Liakopoulos, D. et al. (1998) A novel protein modification pathway related to the ubiquitin system. EMBO J., 17, 2208-2214.
12. Read, M.A. et al. (2000) Nedd8 modification of cul-1 activates SCF(beta(TrCP))-dependent ubiquitination of IkappaBalpha. Mol. Cell. Biol., 20, 2326-2333.
13. Wu, K. et al. (2000) Conjugation of Nedd8 to CUL1 enhances the ability of the ROC1-CUL1 complex to promote ubiquitin polymerization. J. Biol. Chem., 275, 32317-32324.
14. Xirodimas, D.P. et al. (2004) Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell, 118, 83-97.
15. Watson, I.R. et al. (2006) Mdm2-mediated NEDD8 modification of TAp73 regulates its transactivation function. J. Biol. Chem., 281, 34096-34103.
16. Abida, W.M. et al. (2007) FBXO11 promotes the Neddylation of p53 and inhibits its transcriptional activity. J. Biol. Chem., 282, 1797-1804.
17. Oved, S. et al. (2006) Conjugation to Nedd8 instigates ubiquitylation and down-regulation of activated receptor tyrosine kinases. J. Biol. Chem., 281, 21640-21651.
18. Stickle, N.H. et al. (2004) pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Mol. Cell. Biol., 24, 3251-3261.
19. Xirodimas, D.P. et al. (2008) Ribosomal proteins are targets for the NEDD8 pathway. EMBO Rep., 9, 280-286.
20. Gao, F. et al. (2006) Neddylation of a breast cancer-associated protein recruits a class III histone deacetylase that represses NFkappaB-dependent transcription. Nat. Cell Biol., 8, 1171-1177.
21. Karin, M. et al. (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer, 2, 301-310.
22. Ghosh, S. et al. (1990) Activation in vitro of NF-kappa B by phosphorylation of its inhibitor I kappa B. Nature, 344, 678-682.
23. Mercurio, F. et al. (1997) IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science, 278, 860-866.
24. Yaron, A. et al. (1998) Identification of the receptor component of the IkappaBalpha-ubiquitin ligase. Nature, 396, 590-594.
25. Hatakeyama, S. et al. (1999) Ubiquitin-dependent degradation of IkappaBalpha is mediated by a ubiquitin ligase Skp1/Cul 1/F-box protein FWD1. Proc. Natl Acad. Sci. USA, 96, 3859-3863.
26. Mantovani, A. et al. (2008) Cancer and inflammation: a complex relationship. Cancer Lett., 267, 180-181.
27. Hu, Y. et al. (1999) Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase. Science, 284, 316-320.
28. Pikarsky, E. et al. (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature, 431, 461-466.
29. Karin, M. et al. (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol., 5, 749-759.
30. Li, Q. et al. (2005) Inflammation-associated cancer: NF-kappaB is the lynchpin. Trends Immunol., 26, 318-325.
31. Okumura, F. et al. (2010) TRIM8 modulates STAT3 activity through negative regulation of PIAS3. J. Cell Sci., 123, 2238-2245.
32. Hayden, M.S. et al. (2004) Signaling to NF-kappaB. Genes Dev., 18, 2195-2224.
33. Wu, C.J. et al. (2006) Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-kappaB activation. Nat. Cell Biol., 8, 398-406.
34. Tokunaga, F. et al. (2009) Involvement of linear polyubiquitylation of NEMO in NF-kappaB activation. Nat. Cell Biol., 11, 123-132.
35. Chen, Z.J. et al. (1996) Site-specific phosphorylation of IkappaBalpha by a novel ubiquitination-dependent protein kinase activity. Cell, 84, 853-862.
36. Tang, E.D. et al. (2003) A role for NF-kappaB essential modifier/IkappaB kinase-gamma (NEMO/IKKgamma) ubiquitination in the activation of the IkappaB kinase complex by tumor necrosis factor-alpha. J. Biol. Chem., 278, 37297-37305.
37. Ea, C.K. et al. (2006) Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol. Cell, 22, 245-257.
38. Nagler-Anderson, C. (2001) Man the barrier! Strategic defences in the intestinal mucosa. Nat. Rev. Immunol., 1, 59-67.
39. Cusack, J.C.Jr et al. (2001) Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factorkappaB inhibition. Cancer Res., 61, 3535-3540.
40. Hideshima, T. et al. (2006) MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin. Cancer Res., 12, 5887-5894.
41. Ueki, S. et al. (2006) Control of allograft rejection by applying a novel nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin. Transplantation, 82, 1720-1727.
42. Milhollen, M.A. et al. (2010) MLN 4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-kappaB-dependent lymphoma. Blood, 116, 1515-1523.